Loop Capital Initiates Coverage on CVS Health (NYSE:CVS)

ETFS

Equities researchers at Loop Capital began coverage on shares of CVS Health (NYSE:CVSGet Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The firm set a “buy” rating on the pharmacy operator’s stock.

A number of other analysts also recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised their target price on CVS Health from $110.00 to $113.00 in a research note on Thursday, May 5th. Sanford C. Bernstein cut CVS Health from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $122.00 to $112.00 in a report on Thursday, May 26th. Tigress Financial increased their price target on CVS Health from $122.00 to $125.00 in a report on Thursday, April 7th. Finally, StockNews.com started coverage on CVS Health in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, CVS Health presently has an average rating of “Buy” and a consensus price target of $115.84.


NYSE CVS traded down $1.55 during mid-day trading on Thursday, hitting $89.90. The stock had a trading volume of 445,071 shares, compared to its average volume of 6,118,532. CVS Health has a twelve month low of $79.33 and a twelve month high of $111.25. The stock has a market capitalization of $117.89 billion, a price-to-earnings ratio of 14.93, a PEG ratio of 1.47 and a beta of 0.78. The firm’s 50 day moving average is $98.57 and its 200 day moving average is $101.43. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.88 and a quick ratio of 0.62.

CVS Health (NYSE:CVSGet Rating) last issued its earnings results on Wednesday, May 4th. The pharmacy operator reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.08. CVS Health had a return on equity of 15.33% and a net margin of 2.67%. The business had revenue of $76.83 billion during the quarter, compared to the consensus estimate of $75.30 billion. During the same period last year, the company earned $2.04 EPS. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. As a group, equities research analysts expect that CVS Health will post 8.33 earnings per share for the current year.

In other news, EVP Prem S. Shah sold 16,954 shares of CVS Health stock in a transaction dated Friday, April 8th. The stock was sold at an average price of $105.00, for a total value of $1,780,170.00. Following the completion of the transaction, the executive vice president now owns 43,453 shares in the company, valued at approximately $4,562,565. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel P. Finke sold 55,359 shares of CVS Health stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $100.13, for a total value of $5,543,096.67. Following the completion of the transaction, the executive vice president now owns 3,098 shares of the company’s stock, valued at approximately $310,202.74. The disclosure for this sale can be found here. Insiders have sold a total of 77,659 shares of company stock valued at $7,882,993 over the last 90 days. 0.69% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Griffin Asset Management Inc. increased its position in CVS Health by 0.5% during the fourth quarter. Griffin Asset Management Inc. now owns 21,187 shares of the pharmacy operator’s stock worth $2,186,000 after buying an additional 95 shares during the period. Townsend Asset Management Corp NC ADV boosted its stake in shares of CVS Health by 0.6% in the fourth quarter. Townsend Asset Management Corp NC ADV now owns 17,344 shares of the pharmacy operator’s stock valued at $1,789,000 after buying an additional 96 shares in the last quarter. Garrett Investment Advisors LLC boosted its stake in shares of CVS Health by 1.5% in the fourth quarter. Garrett Investment Advisors LLC now owns 6,831 shares of the pharmacy operator’s stock valued at $705,000 after buying an additional 98 shares in the last quarter. First Bancorp Inc ME boosted its stake in shares of CVS Health by 2.8% in the fourth quarter. First Bancorp Inc ME now owns 3,590 shares of the pharmacy operator’s stock valued at $371,000 after buying an additional 98 shares in the last quarter. Finally, Gryphon Financial Partners LLC boosted its stake in shares of CVS Health by 2.0% in the fourth quarter. Gryphon Financial Partners LLC now owns 5,084 shares of the pharmacy operator’s stock valued at $525,000 after buying an additional 99 shares in the last quarter. Institutional investors and hedge funds own 78.00% of the company’s stock.

About CVS Health (Get Rating)

CVS Health Corporation provides health services in the United States. The company’s Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Recommended Stories

The Fly logo

Analyst Recommendations for CVS Health (NYSE:CVS)

Want More Great Investing Ideas?

Receive News & Ratings for CVS Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CVS Health and related companies with MarketBeat.com’s FREE daily email newsletter.




Products You May Like